- Home
- NMR vs GMAB Comparison
NMR vs GMAB Comparison
Compare NMR & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMR
- GMAB
- Stock Information
- Founded
- NMR 1925
- GMAB 1999
- Country
- NMR Japan
- GMAB Denmark
- Employees
- NMR N/A
- GMAB N/A
- Industry
- NMR Investment Bankers/Brokers/Service
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- NMR Finance
- GMAB Health Care
- Exchange
- NMR Nasdaq
- GMAB Nasdaq
- Market Cap
- NMR 16.4B
- GMAB 15.0B
- IPO Year
- NMR 1961
- GMAB N/A
- Fundamental
- Price
- NMR $5.99
- GMAB $20.80
- Analyst Decision
- NMR Hold
- GMAB Buy
- Analyst Count
- NMR 1
- GMAB 8
- Target Price
- NMR N/A
- GMAB $43.00
- AVG Volume (30 Days)
- NMR 483.9K
- GMAB 1.1M
- Earning Date
- NMR 02-05-2025
- GMAB 02-12-2025
- Dividend Yield
- NMR N/A
- GMAB N/A
- EPS Growth
- NMR 108.50
- GMAB 14.35
- EPS
- NMR 0.62
- GMAB 10.80
- Revenue
- NMR $12,446,225,835.00
- GMAB $2,967,926,227.00
- Revenue This Year
- NMR $43.86
- GMAB $32.03
- Revenue Next Year
- NMR N/A
- GMAB $16.97
- P/E Ratio
- NMR $9.19
- GMAB $18.81
- Revenue Growth
- NMR 24.23
- GMAB 17.75
- 52 Week Low
- NMR $4.66
- GMAB $19.85
- 52 Week High
- NMR $6.62
- GMAB $31.88
- Technical
- Relative Strength Index (RSI)
- NMR 60.14
- GMAB 45.42
- Support Level
- NMR $5.52
- GMAB $19.89
- Resistance Level
- NMR $5.89
- GMAB $21.26
- Average True Range (ATR)
- NMR 0.09
- GMAB 0.40
- MACD
- NMR 0.02
- GMAB -0.02
- Stochastic Oscillator
- NMR 100.00
- GMAB 38.16
About NMR Nomura Holdings Inc ADR
Nomura Holdings Inc is a financial services group in Japan and operates offices in countries and regions worldwide including Japan, the U.S., the U.K., Singapore, and the Hong Kong Special Administrative Region ("Hong Kong") through its subsidiaries. The company's clients include individuals, corporations, financial institutions, governments, and governmental agencies. The company's business consists of Wealth Management*, Investment Management, and Wholesale. The company generates the majority of its revenue from the wholesale segment. The Wholesale Division consists of two businesses, Global Markets, which is mainly engaged in the trading, sales, and structuring of financial products, and Investment Banking which is engaged in advisory, financing, and solutions businesses.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.